Dexcom annual ebitda margin
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Dexcom EBITDA Margin Growth & History (DXCM)
Dexcom's ebitda margin was 24.96% for fiscal 2025.
View full Dexcom company overviewDexcom annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 24.96% | +4.68 pp |
| 2024 | 2024-12-31 | 20.28% | −1.36 pp |
| 2023 | 2023-12-31 | 21.64% | +2.83 pp |
| 2022 | 2022-12-31 | 18.80% | +3.78 pp |
| 2021 | 2021-12-31 | 15.02% | −4.01 pp |
| 2020 | 2020-12-31 | 19.03% | +6.09 pp |
| 2019 | 2019-12-31 | 12.94% | +28.18 pp |
| 2018 | 2018-12-31 | −15.24% | −11.56 pp |
| 2017 | 2017-12-31 | −3.67% | +4.86 pp |
| 2016 | 2016-12-31 | −8.53% | +2.99 pp |
| 2015 | 2015-12-31 | −11.52% | −6.46 pp |
| 2014 | 2014-12-31 | −5.05% | +8.63 pp |
| 2013 | 2013-12-31 | −13.69% | +35.46 pp |
| 2012 | 2012-12-31 | −49.15% | +4.59 pp |
| 2011 | 2011-12-31 | −53.74% | +34.54 pp |
| 2010 | 2010-12-31 | −88.27% | +58.09 pp |
| 2009 | 2009-12-31 | −146.36% | — |
Dexcom quarterly ebitda margin
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 29.54% | +5.72 pp |
| Q1 2026 | 2026-03-31 | 27.05% | +8.35 pp |
| Q4 2025 | 2025-12-31 | 30.82% | +8.66 pp |
| Q3 2025 | 2025-09-30 | 25.31% | +4.46 pp |
| Q2 2025 | 2025-06-30 | 23.82% | +2.90 pp |
| Q1 2025 | 2025-03-31 | 18.70% | +2.02 pp |
| Q4 2024 | 2024-12-31 | 22.16% | −3.89 pp |
| Q3 2024 | 2024-09-30 | 20.85% | −5.17 pp |
| Q2 2024 | 2024-06-30 | 20.92% | +1.20 pp |
| Q1 2024 | 2024-03-31 | 16.68% | +4.70 pp |
| Q4 2023 | 2023-12-31 | 26.04% | +6.21 pp |
| Q3 2023 | 2023-09-30 | 26.02% | +1.76 pp |
| Q2 2023 | 2023-06-30 | 19.72% | +2.40 pp |
| Q1 2023 | 2023-03-31 | 11.98% | −0.44 pp |
| Q4 2022 | 2022-12-31 | 19.84% | +15.15 pp |
| Q3 2022 | 2022-09-30 | 24.26% | +2.14 pp |
| Q2 2022 | 2022-06-30 | 17.32% | −3.60 pp |
| Q1 2022 | 2022-03-31 | 12.42% | −0.81 pp |
| Q4 2021 | 2021-12-31 | 4.68% | −17.18 pp |
| Q3 2021 | 2021-09-30 | 22.12% | −0.34 pp |
| Q2 2021 | 2021-06-30 | 20.92% | +2.53 pp |
| Q1 2021 | 2021-03-31 | 13.23% | +1.72 pp |
| Q4 2020 | 2020-12-31 | 21.87% | −3.15 pp |
| Q3 2020 | 2020-09-30 | 22.46% | +5.07 pp |
| Q2 2020 | 2020-06-30 | 18.39% | +15.18 pp |
| Q1 2020 | 2020-03-31 | 11.50% | +13.11 pp |
| Q4 2019 | 2019-12-31 | 25.02% | +71.18 pp |
| Q3 2019 | 2019-09-30 | 17.39% | +9.25 pp |
| Q2 2019 | 2019-06-30 | 3.21% | +2.47 pp |
| Q1 2019 | 2019-03-31 | −1.60% | +11.79 pp |
| Q4 2018 | 2018-12-31 | −46.15% | −53.48 pp |
| Q3 2018 | 2018-09-30 | 8.14% | +6.08 pp |
| Q2 2018 | 2018-06-30 | 0.74% | +6.43 pp |
| Q1 2018 | 2018-03-31 | −13.39% | +12.40 pp |
| Q4 2017 | 2017-12-31 | 7.33% | +8.79 pp |
| Q3 2017 | 2017-09-30 | 2.06% | +11.75 pp |
| Q2 2017 | 2017-06-30 | −5.69% | +6.11 pp |
| Q1 2017 | 2017-03-31 | −25.79% | −12.19 pp |
| Q4 2016 | 2016-12-31 | −1.46% | −5.05 pp |
| Q3 2016 | 2016-09-30 | −9.69% | +28.05 pp |
| Q2 2016 | 2016-06-30 | −11.80% | −10.73 pp |
| Q1 2016 | 2016-03-31 | −13.60% | +0.55 pp |
| Q4 2015 | 2015-12-31 | 3.59% | −1.15 pp |
| Q3 2015 | 2015-09-30 | −37.74% | −33.68 pp |
| Q2 2015 | 2015-06-30 | −1.07% | +5.56 pp |
| Q1 2015 | 2015-03-31 | −14.15% | +7.93 pp |
| Q4 2014 | 2014-12-31 | 4.74% | +5.52 pp |
| Q3 2014 | 2014-09-30 | −4.06% | +5.50 pp |
| Q2 2014 | 2014-06-30 | −6.63% | +16.55 pp |
| Q1 2014 | 2014-03-31 | −22.08% | +8.66 pp |
| Q4 2013 | 2013-12-31 | −0.77% | +18.75 pp |
| Q3 2013 | 2013-09-30 | −9.56% | +56.24 pp |
| Q2 2013 | 2013-06-30 | −23.18% | +32.99 pp |
| Q1 2013 | 2013-03-31 | −30.74% | +39.90 pp |
| Q4 2012 | 2012-12-31 | −19.52% | +30.16 pp |
| Q3 2012 | 2012-09-30 | −65.80% | +1.47 pp |
| Q2 2012 | 2012-06-30 | −56.17% | −25.81 pp |
| Q1 2012 | 2012-03-31 | −70.65% | +7.27 pp |
| Q4 2011 | 2011-12-31 | −49.68% | — |
| Q3 2011 | 2011-09-30 | −67.27% | +39.33 pp |
| Q2 2011 | 2011-06-30 | −30.36% | — |
| Q1 2011 | 2011-03-31 | −77.92% | — |
| Q3 2010 | 2010-09-30 | −106.60% | — |
Dexcom ebitda margin trends
Over the last five fiscal years, Dexcom's ebitda margin increased from 19.03% to 24.96%, a change of +5.93 percentage points. The latest reported quarter, Q2 2026, shows 29.54%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dexcom source filings ↗Community posts
Dexcom raises revenue and margin targets and authorizes a $1 billion buyback
Dexcom ($DXCM) lifted its 2026 sales forecast to $5.20–$5.25 billion, raising the midpoint, and increased its adjusted operating-margin target to approximately 24%. Third-quarter 2026 revenue increased 11% to $1.34 billion, with US growth o ...
